-
Join 674 other subscribers
-
Recent Posts
- Board IPR decisions finding conception and reduction to practice before critical date affirmed
- SCOTUS concludes Amgen’s anti-PCSK9 antibody claims not enabled
- Board IPR claim construction (even with harmless error) and obviousness determination affirmed
- DC findings that Vanda’s method of treatment claims are invalid for obviousness affirmed
- IPR obviousness decision reversed as prior art not shown to be analogous to Sanofi’s claimed invention
Recent Comments
Categories
- America Invents Act
- Analgous Art
- Anticipation (35 USC 102)
- Antitrust
- Appeal
- Arbitration
- Article III disputes
- Assignment / Ownership
- Attorney's Fees
- Bankruptcy
- Best mode
- Biosimilars
- Business methods
- Certificate of Correction
- Claim
- Claim Construction
- Claim Differentiation
- Claim Preclusion
- Claim Vitiation
- Collateral estoppel
- comprising
- Conception and Reduction to Practice
- consisting of
- Contributory Infringement
- Copyright
- Covered Business Method Reviews
- Damages
- Derivation of Invention
- Design Patents
- Diligence
- Disclaimers
- Discovery
- Doctrine of equivalents
- Double Patenting
- Enablement
- Equitable estoppel
- Exhaustion and Repair
- Experimental Use
- Expert Testimony
- Extension (156)
- False Marking
- Functional limitations
- Generics / ANDA
- Importation
- Incorporation by Reference
- Indefiniteness
- Inducement to Infringe
- Inequitable Conduct
- Infringement
- Inherency
- Injunction
- Inter Parties Review (IPR)
- Interference
- International Trade Commission
- Intervening Rights
- Inventorship
- IPR
- Issue Preclusion
- Jurisdiction
- Laches
- Licensing
- Lost Profits
- Malpractice
- Markush
- Means-plus-function
- Medical Devices
- Method claims
- Negative Limitations
- Obviousness
- Obviousness (Secondary Considerations)
- Obviousness-Teaching Away
- On-Sale Bar
- Patent Eligibility (101)
- Patent Exhaustion
- Patent Marking
- Patent Prosecution
- Patent Term Adjustment (PTA)
- Patent Term Extension
- Patentability
- Post-grant review
- Preamble
- Priority
- Privilege
- Procedural Issues
- Product-by-Process
- Prosecution History Estoppel
- Public Accessibility
- Public Use
- Ranges
- Reexamination
- Reissue
- Royalties
- Safe Harbor, FDA exemptions (271(e)(1))
- Section 101 (see also Patentability)
- Software
- State Sovereignty
- Summary Judgment
- Terminal Disclaimers
- Trade Dress
- Trade Secret
- Trademarks
- U.S. Supreme Court
- Uncategorized
- Unenforceability
- Unjust enrichment
- Utility
- Venue
- Wherein
- Willfullness
- Written description
Archives
- June 2023
- May 2023
- April 2023
- March 2023
- February 2023
- January 2023
- December 2022
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- July 2011
- February 2011
- January 2011
Meta
- Anticipation (35 USC 102) Appeal Article III disputes Assignment / Ownership Attorney's Fees Claim Construction Claim Differentiation Damages Doctrine of equivalents Enablement Generics / ANDA Indefiniteness Inducement to Infringe Infringement Inter Parties Review (IPR) Inventorship IPR Licensing Means-plus-function Obviousness Obviousness-Teaching Away Patentability Patent Eligibility (101) Prosecution History Estoppel Reexamination Software Trademarks Uncategorized Willfullness Written description
Copyright Notice
© Patrick J. Halloran, Ph.D., J.D. and lifescienceip.wordpress.com, [2011-2017]. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Patrick J. Halloran, Ph.D., J.D. and lifescienceip.wordpress.com with appropriate and specific direction to the original content.
Monthly Archives: December 2014
Hoyt A. Fleming v. Escort Inc. and Beltronics USA, Inc.
Docket No. 2014-1331, -1371 TARANTO, BRYSON, HUGHES December 24, 2014 Brief Summary: Evidence of prior invention was found to be sufficient and there was no evidence “suppression, concealment, or abandonment” between conception and reduction to practive. Fleming’s failure to “appreciate … Continue reading
Top 2014 science stories from Science Magazine!
It’s not from The Federal Circuit, but check out Science’s top 2014 stories
Posted in Uncategorized
Leave a comment
Content Extraction and Transmission LLC v. Wells Fargo Bank, et al. Diebold, Incorporated v. Content Extraction and Transmission LLC et al.
Docket No. 2013-1588, -1589, 2014-1112, -1687 DYK, TARANTO, CHEN December 23, 2014 Brief Summary: CET’s methods deemed invalid under 35 USC § 101 (“There is no ‘inventive concept’ in CET’s use of a generic scanner and computer to perform well-understood, … Continue reading
Posted in Business methods, Patentability
Leave a comment
Aqua Shield v. Inter Pool Cover Team et al.
Docket No. 2013-1668 PROST, NEWMAN, HUGHES December 19, 2014 Brief Summary: Actual profits are not a cap on a reasonably royalty. The DC erred in not considering willfulness under the Seagate standards. Summary: Aqua Shield appealed DC royalty determination (set … Continue reading
Posted in Infringement, Royalties, Willfullness
Leave a comment
GlaxoSmithKline LLC v. Banner Pharmacaps, Inc. et al.
Docket No. 2013-1593, -1594, -1595, -1598 O’MALLEY, WALLACH, TARANTO February 24, 2014 Brief Summary: Term “solvate” found not to require any “performance property…and hence raises no issue of insufficnet structural, creation-process, or other descriptions to support such a property” (e.g., … Continue reading
Arlington Industries, Inc. v. Bridgeport Fittings, Inc.
Docket No. 2013-1400, -1401 PROST, LOURIE, LINN August 29, 2014 Non-precedential Brief Summary: Board agreement with examiner’s final rejection affirmed because prior art disclosure would not require “substantial reengineering”, there was no teaching away, and the secondary considerations were unpersuasive … Continue reading
Posted in Obviousness, Reexamination, Uncategorized
Leave a comment
Stryker Corp. et al. v. Zimmer et al.
Docket No. 2013-1668 PROST, NEWMAN, HUGHES December 19, 2014 Update: SCOTUS cert. granted 10/19/15 Brief Summary: Findings of infringement affirmed but willfulness determination reversed because “Zimmer presented reasonable defenses to all of the asserted claims of Stryker’s patents”. Summary: Zimmer … Continue reading
In re BRCA1- and BRCA2-Based Hereditary Cancer Test Patent Litigation Univ. Utah Res. Found. et al. (“Myriad”) v. Ambry Genetics Corp.
Docket No. 2014-1361, -1366 PROST, CLEVENGER, DYK December 17, 2014 Brief Summary: Myriad’s primer pair composition claims found patent ineligible as “structurally identical to the ends of DNA strands found in nature”. Its method claims found patent ineligible under the … Continue reading
Posted in Patentability
Leave a comment
Japanese Foundation for Cancer Research v. Michelle K. Lee and USPTO
Docket No. 2013-1678, 2014-1014 PROST, DYK, TARANTO December 9, 2014 Brief Summary: PTO denial of withdrawal of Attorney’s erroneously filed terminal disclaimer not arbitrary or capricious as PTO determined miscommunications between the Foundation and its attorney of record did not … Continue reading
Posted in Disclaimers
Leave a comment
Promega Corp. et al. v. Life Technologies Corp. et al.
Docket No. 2013-1011, -1029, -1376 PROST(D), MAYER, CHEN December 15, 2014 Update, SCOTUS opinion (2/22/17): FC erred in its decision as “[t]he supply of a single component of a multi-component invention for manufacture abroad does not give rise to liability … Continue reading
Posted in Enablement, Infringement, Uncategorized
Leave a comment
Federal Circuit summaries 